Editorial commentary: Clinical significance of HIV subtype variability in regard to treatment outcome

Clinical Infectious Diseases

Volumn 60, Issue 10, 2015, Pages 1550-1551

  Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

clinical outcome; HIV subtype; K65R; resistance; V106M

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DIDANOSINE; DORAVIRINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; NONHUMAN; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRAL GENETICS; VIRUS LOAD; CLASSIFICATION; DRUG EFFECTS; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE;

DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE;

EID: 84929223963     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ107     Document Type: Note

References (9)

1. Kantor R, Smeaton L, Vardhanabhuti S, et al. Pretreatment HIV drug resistance and HIV-1 subtype C are independently associated with virologic failure: results from the multinational PEARLS (ACTG A5175) clinical trial. Clin Infect Dis 2015; 60:1541-9.
2. Kuritzkes DR. HIV-1 subtype as a determinant of disease progression. J Infect Dis 2008; 197:638-9.
3. Li JZ, Paredes R, Ribaudo HJ, et al. Lowfrequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011; 305:1327-35.
4. Li JF, Lipscomb JT, Wei X, et al. Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J Infect Dis 2011; 203:798-802.
5. Sunpath H, Wu B, Gordon M, et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. AIDS 2012; 26:1679-84.
6. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003; 17:F1-5.
7. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006; 50:4182-5.
8. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med 2011; 365:637-46.
9. Feng M,Wang D, Grobler JA, et al. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother 2015; 59:590-8.